[go: up one dir, main page]

KR930004234A - 메타노안트라센 화합물 - Google Patents

메타노안트라센 화합물 Download PDF

Info

Publication number
KR930004234A
KR930004234A KR1019920014635A KR920014635A KR930004234A KR 930004234 A KR930004234 A KR 930004234A KR 1019920014635 A KR1019920014635 A KR 1019920014635A KR 920014635 A KR920014635 A KR 920014635A KR 930004234 A KR930004234 A KR 930004234A
Authority
KR
South Korea
Prior art keywords
formula
pyridyl
chloro
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920014635A
Other languages
English (en)
Other versions
KR100233209B1 (ko
Inventor
톰즈 제이컵스 로버트
존 온마크트 사이러스
에이미 트레이너 다이안
Original Assignee
수잔 제인 젠틀
임페리얼 케미칼 인더스트리스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117644A external-priority patent/GB9117644D0/en
Priority claimed from GB929207539A external-priority patent/GB9207539D0/en
Application filed by 수잔 제인 젠틀, 임페리얼 케미칼 인더스트리스 피엘씨 filed Critical 수잔 제인 젠틀
Publication of KR930004234A publication Critical patent/KR930004234A/ko
Application granted granted Critical
Publication of KR100233209B1 publication Critical patent/KR100233209B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음.

Description

메타노안트라센 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용 가능한 염：
    상기식에서, X 및 Y는 수소 및 할로로부터 독립적으로 선택되고；R2는 하기 일반식 (Ia)-(Ic)로 나타낸 구조로 부터 선택된다.
    상기식에서, R3는 (3-6C)시클로 알킬；(1-6C)알킬；(1-6C)알킬, (1-6C)알콕시, 히드록시, 할로, 시아노, 니트로, 벤조일, 일반식 SO2NRaRb을 갖는 디(1-6C)알킬아미노(1-6C)알킬 아미노설포닐 및 일반식 CONRcRd를 갖는 아미노카르보닐로 구성된 군으로부터 독립적으로 선택된 0-3개의 치환체를 각각 함유하는 페닐 및 나프틸(이때, Ra, Rb, Rc및 Rd는 수소 및(1-6C)알킬로부터 독립적으로 선택되거나, 또는 Ra, Rb, Rc및 Rd각각이 결합되어 있는 질소원자와 함께 5-원 또는 6-원 헤테로시클릭 고리를 형성하며, 상기의 질소는 유일한 이종원자이다)；질소, 산소 및 황으로부터 선택된 1-3개의 이종원자를 함유하고, 히드록시, (1-6C)알킬, (1-6C)알콕시, (1-6C)히드록시알킬, 페닐, 클로로 및 플루오로로부터 선택된 0-2개의 치환체를 함유할 수 있는 5-원 및 6-원 헤테로아릴고리 및 이의 벤즈 유도체로부터 선택되고；R4는 수소 및 (1-6C)알킬로부터 선택된다.
  2. 제1항에 있어서, X 및 Y는 수소 및 클로로로부터 독립적으로 선택되며, (a) R2가 상기 일반식 (Ia)일때, R3는 2-피리딜 및 3-피리딜로부터 선택되고, R4는 수소 및 메틸로부터 선택되며；(b) R2가 상기 일반식(Ib)일때, R3는 3-피리딜이며；(c) R2가 상기 일반식(Ic)일때, R3는 2-히드록시-3-피리딜이고, R4는 수소인 화합물.
  3. 하기로 구성된 군으로부터 선택된 화합물：R-1-〔((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；S-1-〔1-((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；(R,S)-1-〔1-9RS,10RS)-(2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；1-((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-(2-히드록시-3-피리딜메틸)피페리딘；1-((9RS,10RS)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-(2-히드록시-3-피리딜메틸)피페리딘.
  4. 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 약학적 조성물：
    상기식에서, X 및 Y는 수소 및 할로로부터 독립적으로 선택되고；R2는 하기 일반식 (Ia)-(Ic)로 나타낸 구조로 부터 선택된다：
    식에서, R3는 (3-6C)시클로알킬；(1-6C)알킬；(1-6C)알킬, (1-6C)알콕시, 히드록시, 할로, 시아노, 니트로, 벤조일, 일반식 SO2NRaRb을 갖는 디(1-6C)알킬아미노(1-6C)알킬 아미노설포닐 및 일반식 CONRcRd를 갖는 아미노카르보닐로 구성된 군으로부터 독립적으로 선택된 0-3개의 치환체를 각각 함유하는 페닐 및 나프틸(이때, Ra, Rb, Rc및 Rd는 수소 및(1-6C)알킬로부터 독립적으로 선택되거나, 또는 Ra, Rb, Rc및 Rd각각이 결합되어 있는 질소원자와 함께 5-원 또는 6-원 헤테로시클릭 고리를 형성하며, 상기의 질소는 유일한 이종원자이다)；질소, 산소 및 황으로부터 선택된 1-3개의 이종원자를 함유하고, 히드록시, (1-6C)알킬, (1-6C)알콕시, (1-6C)히드록시알킬, 페닐, 클로로 및 플루오로로부터 선택된 0-2개의 치환체를 함유할 수 있는 5-원 및 6-웬 헤테로아릴고리 및 이의 벤즈 유도체로부터 선택되고；R4는 수소 및 (1-6C)알킬로부터 선택된다.
  5. 제4항에 있어서, X 및 Y는 수소 및 클로로로부터 독립적으로 선택되며, (a) R2가 상기 일반식 (Ia)일때, R3는 2-피리딜 및 3-피리딜로부터 선택되고, R4는 수소 및 메틸로부터 선택되며；(b) R2가 상기 일반식 (Ib)일때, R3는 3-피리딜이며；(c) R2가 상기 일반식 (Ic)일때, R3는 2-히드록시-3-피리딜이고, R4는 수소이다.
  6. 제5항에 있어서, 상기 화합물이 하기로 부터 선택된 조성물：R-1-〔1-((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；S-1-〔1-((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；(R,S)-1-〔1-9RS,10RS)-(2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-피페리딜〕-1-(3-피리딜)메탄올；1-((9S,10S)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-(2-히드록시-3-피리딜메틸)피페리딘；1-((9RS,10RS)-2-클로로-9,10-디히드로-9,10-메타노안트라센-9-일메틸)-4-(2-히드록시-3-피리딜메틸)피페리딘.
  7. (a) R2가 하기 일반식 (Ia)일대, 일반식(II)의 상응하는 아미드를 환원시키고；(b) R2가 하기 일반식(Ia)이고, R4가 수소일때, 하기 일반식(III)의 상응하는 알데히드를 일반식 R3Li의 사용하는 알킬리튬 화합물로 처리하고；(c) R2가 하기 일반식(Ia)이고, R4가 수소일때, 하기 일반식(III)의 상응하는 알데히드를 Z가 할로기인 일반식R3MgZ의 마그네슘 할리이드로 처리하고；(d) R2가 하기 일반식(Ia)이고, R4가 (1-6C) 알킬일때, 하기 일반식(IV)의 케톤을 Z가 할로기인 일반식R4MgZ의 상응하는 알킬마그네슘 할라이드로 처리하고；(e) R2가 하기 일반식(Ia) 이고, R4가 (1-6C)알킬일때, 하기 일반식(IV)의 케톤을 일반식 R4Li의 상응하는 알킬리튬 화합물로 처리하고；(f) R2가 하기 일반식(Ib)일때, 하기 일반식(V)의 상응하는 알콜을 산화시키고；(g) R2가 하기 일반식(Ic)일때, 하기 일반식(VI)의 상응하는 알콜을 환원시키고, 이후에, 약학적으로 허용가능한 염의 요구될때, 통상적인 방법으로 상기 화합물을 적당한 산과 반응시키는 것을 특징으로 하는 제1항 내지 제3항중 어느 한 항에서 정의된 화합물을 제조하는 방법：
    식중, X, Y, R3및 R4는 제2항에서 주어진 의미를 갖는다.
  8. X, Y, R3및 R4가 제1항에서 주어진 의미를 갖는 하기 일반식(II)의 화합물.
  9. X, Y, R3가 제1항에서 주어진 의미를 갖는 하기 일반식(V)의 화합물.
  10. X, Y, R3및 R4가 제1항에서 주어진 의미를 갖는 하기 일반식(VI)의 화합물：
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920014635A 1991-08-15 1992-08-14 메타노안트라센 화합물 Expired - Fee Related KR100233209B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919117644A GB9117644D0 (en) 1991-08-15 1991-08-15 Amine derivatives
GB9117644.6 1991-08-15
GB9207539.9 1992-04-07
GB929207539A GB9207539D0 (en) 1992-04-07 1992-04-07 Therapeutic agents

Publications (2)

Publication Number Publication Date
KR930004234A true KR930004234A (ko) 1993-03-22
KR100233209B1 KR100233209B1 (ko) 1999-12-01

Family

ID=26299413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920014635A Expired - Fee Related KR100233209B1 (ko) 1991-08-15 1992-08-14 메타노안트라센 화합물

Country Status (20)

Country Link
US (3) US5399568A (ko)
EP (1) EP0532177B1 (ko)
JP (1) JP3281047B2 (ko)
KR (1) KR100233209B1 (ko)
AT (1) ATE144252T1 (ko)
AU (1) AU652653B2 (ko)
CA (1) CA2076168A1 (ko)
CZ (1) CZ251892A3 (ko)
DE (1) DE69214586T2 (ko)
DK (1) DK0532177T3 (ko)
ES (1) ES2092645T3 (ko)
FI (1) FI923662L (ko)
GB (1) GB9216297D0 (ko)
GR (1) GR3021399T3 (ko)
HU (1) HUT66623A (ko)
IE (1) IE922587A1 (ko)
IL (1) IL102806A0 (ko)
NO (1) NO923198L (ko)
NZ (1) NZ243954A (ko)
TW (1) TW222622B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
US5514683A (en) * 1992-02-20 1996-05-07 James Black Foundation Limited Bicyclo 2,2,2!octane derivatives
US5530012A (en) * 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
MX2008006076A (es) 2005-11-09 2008-12-16 Combinatorx Inc Metodos, composiciones y kits para el tratamiento de condiciones medicas.
CN101679357A (zh) * 2007-05-09 2010-03-24 辉瑞大药厂 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE610863A (fr) * 1960-11-29 1962-05-28 Ciba Geigy Procédé de préparation de nouvelles amines, entre autres de 9-amino-alcoyl-9,10-dihydro-9,10-éthano-(1,2)-anthracènes
US3632653A (en) * 1960-11-29 1972-01-04 Ciba Geigy Corp Ethano-anthracenes
BE674185A (ko) * 1961-10-10
FR176F (ko) * 1965-05-19
US3489799A (en) * 1967-09-26 1970-01-13 Ciba Geigy Corp Ethano-anthracenes
ES367292A1 (es) * 1968-05-16 1971-05-01 Ciba Geigy Procedimiento para la obtencion de 9-(aminoalquilo)-9,10- dihidro - 9,10-etanoantracenos sustituidos.
US3706765A (en) * 1969-01-03 1972-12-19 Ciba Geigy Corp Hydroxyethano-anthracenes
CH532553A (de) * 1969-03-25 1973-01-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen N-substituierten 9-NAminoalkyl)-12-acyloxy-9,10-dihydro-9,10-äthano-anthrazenen
DE2021668A1 (de) * 1969-05-10 1970-11-19 Ciba Geigy Neue Amine und Verfahren zu ihrer Herstellung
US3870796A (en) * 1970-11-27 1975-03-11 Ciba Geigy Corp Pharmaceutical preparation
US4045580A (en) * 1971-02-23 1977-08-30 Ciba-Geigy Corporation Pharmaceutical preparation using 9-(2-hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes as antidepressants
US4017542A (en) * 1971-02-23 1977-04-12 Ciba-Geigy Corporation 9-(2-Hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes and salts thereof
JPS5911576B2 (ja) * 1975-07-07 1984-03-16 住友化学工業株式会社 新規なメタノ−アントラセン誘導体の製造法
US4224344A (en) * 1974-12-13 1980-09-23 Sumitomo Chemical Company, Limited Organic tricyclic compounds
US4358620A (en) * 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
JPS527972A (en) * 1975-07-07 1977-01-21 Sumitomo Chem Co Ltd Process for preparing novel morpholine derivatives
JPS5268170A (en) * 1975-12-03 1977-06-06 Sumitomo Chem Co Ltd Preparation of novel methano-anthracene derivatives
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
JPS5910654B2 (ja) * 1976-04-07 1984-03-10 住友化学工業株式会社 新規なメタノ−アントラセン誘導体
JPS5936621B2 (ja) * 1976-05-19 1984-09-05 大塚製薬株式会社 新規なカルボスチリル誘導体
US4318926A (en) * 1979-08-14 1982-03-09 Ciba-Geigy Corporation Method of curing or alleviating herpes infections and pharmaceutical compositions suitable therefor
US5226570A (en) * 1991-07-16 1993-07-13 Fabio Pedrini Self-centering roof rack
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
GB9117639D0 (en) * 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JP3005175U (ja) 1993-08-23 1994-12-13 有限会社サンエイ レンタルショップ用ビデオケース

Also Published As

Publication number Publication date
US5550136A (en) 1996-08-27
GR3021399T3 (en) 1997-01-31
DE69214586D1 (de) 1996-11-21
HU9202641D0 (en) 1992-10-28
IE922587A1 (en) 1993-02-24
AU652653B2 (en) 1994-09-01
ES2092645T3 (es) 1996-12-01
CZ251892A3 (en) 1993-02-17
EP0532177A1 (en) 1993-03-17
JP3281047B2 (ja) 2002-05-13
NO923198D0 (no) 1992-08-14
JPH05246988A (ja) 1993-09-24
FI923662L (fi) 1993-02-16
IL102806A0 (en) 1993-01-31
FI923662A0 (fi) 1992-08-14
HUT66623A (en) 1994-12-28
KR100233209B1 (ko) 1999-12-01
EP0532177B1 (en) 1996-10-16
DK0532177T3 (da) 1997-03-24
AU2101792A (en) 1993-02-18
NO923198L (no) 1993-02-16
NZ243954A (en) 1995-09-26
TW222622B (ko) 1994-04-21
ATE144252T1 (de) 1996-11-15
GB9216297D0 (en) 1992-09-16
US5719166A (en) 1998-02-17
DE69214586T2 (de) 1997-03-20
US5399568A (en) 1995-03-21
CA2076168A1 (en) 1993-02-16

Similar Documents

Publication Publication Date Title
ATE73797T1 (de) Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel.
RU2219177C2 (ru) Производные бензотиадиазолов, бензоксадиазолов и бензодиазинов, способ их получения и фармацевтическая композиция
KR930004262A (ko) 메타노안트라센 화합물
MA21719A1 (fr) Procede de preparation de piperidines et de composes les contenant .
AU6823590A (en) New (1-naphtyl)piperazine derivatives, process for preparing these and pharmaceutical compositions containing them
GB1014053A (en) 7-hydroxy-coumarin derivatives and process for their production
US3723433A (en) Pyrimidinylpyrazole derivatives and methods for preparing the same
KR900001707A (ko) (아자)나프탈렌설탐 유도체, 그들의 제조 및 그들을 포함한 조성물
KR840006633A (ko) 벤족사졸리논 유도체의 제조방법
KR840001167A (ko) 티아졸리딘알킬렌 피페라진 유도체의 제조방법
RU2000124402A (ru) Производные азетидина и пирролидина
KR890014520A (ko) 이소인돌리논 유도체, 그 제조방법 및 이를 함유한 약품
YU48071B (sh) DERIVTI (w/4-(2-PIRIMIDINIL)-1-PIPERAZINIL/ALKIL)-1H-AZOLA I POSTUPAK NJIHOVOG DOBIJANJA
KR930004234A (ko) 메타노안트라센 화합물
ATE19776T1 (de) Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DK326481A (da) Fremgangsmaade til fremstilling af i 5-stillingen substituerede 5,10-dihydro-11h-dibenzo (b,e) (1,4) diazepin-11-oner eller syreadditionssalte deraf
NO20002351L (no) Nye substituerte pyridin- eller piperidinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
DK19182A (da) Fremgangsmaade til fremstilling af phenylpiperazinyl-propaner af heterylphenoler
KR890016018A (ko) 6-옥소-피리다진 유도체류, 이들 화합물의 제조방법과 그 함유 의약품
KR880013881A (ko) 하이드라진 유도체, 그들의 제조방법 및 그들이 함유된 약제학적 조성물
KR840001166A (ko) 스피로티아졸리딘일 피페라진 유도체 제조방법
ATE20063T1 (de) 3-pyridyl-5-alkoxy(oder phenoxy- oder aralkyloxy- )pyrazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
KR890002079A (ko) 1-[2-(페닐메틸)페닐]피페라진 및 그의 제조방법
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
KR920008020A (ko) 피레라진 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920814

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970814

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920814

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990407

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19990721

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990910

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990911

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20030610